Paper Details

  1. Home
  2. Paper Details

Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.

Author: BeuersUlrich, JansenLouis, KootMaarten, KuikenSjoerd D, MolenkampRichard, ReesinkHendrik W, StelmaFemke, TakkenbergR Bart, VerheijJoanne, WeijerSebastiaan, WillemseSophie B, ZaaijerHans L, de NietAnnikki, van NieuwkerkCarin M J

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigates the effectiveness of peg-interferon-alfa-2a (peg-IFN) and nucleotide analogue combination therapy in achieving HBsAg loss in patients with chronic hepatitis B and a low viral load. While antiviral treatment is not currently recommended for these patients, the study aims to assess whether achieving a functional cure is possible.
Paper Details　
Original Abstract of the Article :
Antiviral treatment is currently not recommended for patients with chronic hepatitis B with a low viral load. However, they might benefit from acquiring a functional cure (hepatitis B surface antigen [HBsAg] loss with or without formation of antibodies against hepatitis B surface antigen [anti-HBs])...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2468-1253(17)30083-3

データ提供：米国国立医学図書館（NLM）

Treating Chronic Hepatitis B: A New Oasis in the Desert

This study, like a caravan seeking a cure in the desert of chronic hepatitis B, explores the effectiveness of peg-interferon-alfa-2a (peg-IFN) and nucleotide analogue combination therapy in treating patients with chronic hepatitis B (CHB) with a low viral load. The researchers conducted a randomized controlled trial involving patients with CHB and a low viral load, comparing the effects of the combination therapy to no treatment. The study revealed that the combination therapy was associated with a significant increase in HBsAg loss, suggesting its potential to achieve a functional cure for CHB. This finding has important implications for treatment strategies for patients with CHB, particularly those with low viral loads.

The Promise of Combination Therapy for Chronic Hepatitis B

This study offers hope for patients with chronic hepatitis B, particularly those with low viral loads. The combination therapy, involving peg-IFN and nucleotide analogues, has shown promising results in achieving HBsAg loss, potentially leading to a functional cure. This finding encourages further research and clinical application of this treatment strategy.

Navigating the Desert of Hepatitis B

This study sheds light on the potential of combination therapy for chronic hepatitis B. It provides a valuable tool for clinicians in managing this challenging condition, particularly for patients with low viral loads. The findings encourage further research and clinical application to optimize treatment strategies and improve patient outcomes.

Dr.Camel's Conclusion

This study offers a promising oasis in the desert of chronic hepatitis B, highlighting the potential of combination therapy to achieve a functional cure for patients with low viral loads. The findings encourage further research and clinical application to optimize treatment strategies and improve patient outcomes.
Date :
  1. Date Completed 2018-09-25
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28522204

DOI: Digital Object Identifier

10.1016/S2468-1253(17)30083-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.